Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations

Adoptive T cellular immunotherapies have emerged as relevant approaches for treating cancer patients who have relapsed or become refractory (R/R) to traditional cancer treatments. Chimeric antigen receptor (CAR) T-cell therapy has improved survival in various hematological malignancies. However, significant limitations still impede the widespread adoption of these therapies in most cancers. To advance in this field, six research groups have created the “NEXT Generation CART MAD Consortium” (NEXT CART) in Madrid’s Community, which aims to develop novel cell-based immunotherapies for R/R and poor prognosis cancers. At NEXT CART, various basic and translational research groups and hospitals in Madrid concur to share and synergize their basic expertise in immunotherapy, gene therapy, and immunological synapse, and clinical expertise in pediatric and adult oncology. NEXT CART goal is to develop new cell engineering approaches and treatments for R/R adult and pediatric neoplasms to evaluate in multicenter clinical trials. Here, we discuss the current limitations of T cell-based therapies and introduce our perspective on future developments. Advancement opportunities include developing allogeneic products, optimizing CAR signaling domains, combining cellular immunotherapies, multi-targeting strategies, and improving tumor-infiltrating lymphocytes (TILs)/T cell receptor (TCR) therapy. Furthermore, basic studies aim to identify novel tumor targets, tumor molecules in the tumor microenvironment that impact CAR efficacy, and strategies to enhance the efficiency of the immunological synapse between immune and tumor cells. Our perspective of current cellular immunotherapy underscores the potential of these treatments while acknowledging the existing hurdles that demand innovative solutions to develop their potential for cancer treatment fully

Cardiomiopatía no compacta. Conocerla para sospecharla

Introducción: La cardiopatía no compacta descrita desde 1926 (1), se caracteriza por trabeculaciones anormales del ventrículo izquierdo, principalmente en el ápex, pueden asociarse a hipertrofia, dilatación, disfunción diastólica o sistólica e incluso comprometer ambos ventrículos(2). Es frecuentemente asociada a defectos genéticos y diferentes tipos de enfermedad cardiaca congénita(3), se ha descrito hasta en un 3.7 % en adultos con FeVi < al 45 %(4) y una amplia variedad de manifestaciones clínicas no siempre asociadas a estados patológicos. Revista Colombiana de Cardiología (2021) Vol. 28 Supl. 1 p.2

Diagnóstico multimodal de masas intracardiacas: lo oculto dentro de lo evidente

Introducción: Es poco usual que en nuestra práctica nos enfrentemos al diagnóstico de masas intracardiacas, las cuales cuentan con un amplio espectro de etiologías como tumores benignos y malignos (primarios o secundarios), llegando a contar con características similares imagenológicas a trombos, vegetaciones, lesiones calcificadas e incluso compartir características similares con algunas variantes anatómicas estructurales. Con el advenimiento de la multimodalidad en imagen cardiaca se nos ha permitido tener mayor aproximación al diagnóstico de masas intracardiacas, aunque el diagnóstico definitivo sea histopatológico.https://orcid.org/0000-0002-4058-312Xhttps://orcid.org/0000-0003-2568-4667https://orcid.org/0000-0002-9297-106